Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Ting-ying
Contact Ting-ying, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck RackActions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Articles
Pulsatile FXR activation: Timing bile acid-targeted therapy to physiology
Therapeutic activation of farnesoid X receptor (FXR) has long been pursued as a way to correct bile acid dysregulation in chronic liver diseases, but high affinity long-acting FXR agonists have often faced a narrow therapeutic window. Recently, Zang, Shi, Zhao et al. reported that linafexor (CS0159) is a first-in-class, non-bile-acid FXR agonist designed for rapid clearance and transient receptor activation [1].
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ting-ying
Contact Ting-ying, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack